Repair Biotechnologies

This position is responsible for independently executing in vitro and in vivo studies, and supporting more senior colleagues.

Repair Biotechnologies aims to degrade cholesterol and treat diseases.

This position is responsible for independently developing and executing in vitro and in vivo studies, and managing and mentoring junior colleagues.

Bobby Khan is chief medical officer of Repair Biotechnologies and a cardiologist and clinical investigator. He is a professor of medicine at the University of Central Florida School of Medicine and has published nearly 90 peer-reviewed articles on cardiovascular and metabolic disorders.

Dr. Karlsberg is board certified in internal medicine and cardiovascular disease and certified in comprehensive echocardiography, nuclear cardiology, and level III cardiovascular CT. He is on the clinical faculty at NYU Langone Health.

Richard Honkanen invented the technology underlying Repair Biotechnologies’ CDP platform and is a professor of biochemistry and molecular biology at the University of South Alabama. His lab studies atherosclerosis and other age-related diseases.

Repair Biotechnologies provides information about its progress and plans.

Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading Platform (CDP) therapy solves this.

Repair Biotechnologies, Inc. has a privacy policy describing how it collects, uses, communicates, and discloses personal information and how it makes use of that information.